Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes

[Background]: Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been identified. Type and number of somatic mutations have been associated with prognosis and response to t...

Descripción completa

Detalles Bibliográficos
Autores: Caballero, Juan Carlos, Dávila, Julio, López-Pavía, María, Such, Esperanza, Bernal, Teresa, Ramos, Fernando, Calabuig, Marisa, Hernandez-Sánchez, Jesus M., Pomares, Helena, Sánchez Barba, Mercedes, Abáigar, María, González, Bernardo, Merchán, Brayan, Sancho-Tello, Reyes, Callejas, Marta, Muñoz-Novas, Carolina, Cerveró, Carlos, Sanz, Guillermo, Hernández, Jesús M., Díez-Campelo, María
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/381460
Acceso en línea:http://hdl.handle.net/10261/381460
Access Level:acceso abierto
Palabra clave:Erythropoiesis stimulating agents
Lower-risk myelodysplastic syndromes
Myelodysplastic syndromes
Next generation sequencing
Somatic mutations
Descripción
Sumario:[Background]: Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been identified. Type and number of somatic mutations have been associated with prognosis and response to therapies in MDS patients.

Similares en LA Referencia